CRUSH PAD: Real-world Outcomes Following Use of Shockwave Intravascular Lithotripsy (IVL) Technology in Calcified Common Femoral Lesions

Who May Qualify: - Subjects presenting with claudication or CLI by Rutherford Clinical Category 2, 3, 4, 5, or 6 of the target limbs - Subject is a suitable candidate for angiography and endovascular intervention per the latest clinical guidelines - Patient is scheduled to undergo treatment with Shockwave Intravascular Lithotripsy (IVL) technology followed by standard of care treatment with DCB, BMS, DES at the physician's discretion. Angiographic Inclusion Criteria - Target lesion that is located in a native, de novo common femoral artery - Target lesion reference vessel diameter is between 4.0mm and 7.0mm by visual estimate. - Target lesion is ≥70% stenosis by investigator via visual estimate. - Target lesion length is ≤50mm for lesions 70-99% stenosed. Target lesion can be all or part of the 50mm treated zone. - Chronic total occlusion, lesion length is ≤50mm of the total ≤50 mm target lesion. - Calcification is at least moderate defined as presence of fluoroscopic evidence of calcification: 1) on parallel sides of the vessel and 2) extending \> 50% the length of the lesion if lesion is ≥50mm in length; or extending for minimum of 20mm if lesion is \<50mm in length. Who Should NOT Join This Trial: - Subjects with any medical condition that would make him/her an inappropriate candidate for treatment with Shockwave Medical Peripheral Lithoplasty® System as per Instructions for Use (IFU) or investigator's opinion. - Subject is already enrolled in other investigational (interventional) studies that would interfere with study endpoints. - Cognitive impairment as documented in medical records - Not speaking English or Spanish - Currently a prisoner - Pregnancy or nursing - Estimated survival less than 12 months at the time of screening - Prior history of CFA endarterectomy Always talk to your doctor about whether this trial is right for you.